Lipid-like properties and pharmacology of the anthelmintic macrocyclic lactones

Bibliography

• Campbell WC. History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents. Curr Pharm Biotechnol 2012;13(6):853-65
   PubMed Web of Science ®Google Scholar
• Geary TG, Moreno Y. Macrocyclic lactone anthelmintics: spectrum of activity and mechanism of action. Curr Pharm Biotechnol 2012;13(6):866-72
   PubMed Web of Science ®Google Scholar
• McKellar QA, Gokbulut C. Pharmacokinetic features of the antiparasitic macrocyclic lactones. Curr Pharm Biotechnol 2012;13(6):888-911
   PubMed Web of Science ®Google Scholar
• Molyneux DH, Bradley M, Hoerauf A, et al. Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol 2003;19(11):516-22
   PubMed Web of Science ®Google Scholar
• McKellar QA, Scott EW. The benzimidazole anthelmintic agents--a review. J Vet Pharmacol Ther 1990;13(3):223-47
   PubMed Web of Science ®Google Scholar
• Campbell W. editor. Ivermectin and abamectin. Springer-Verlag; New York: 1989
   Google Scholar
• Lespine A, Dupuy J, Alvinerie M, et al. Interaction of macrocyclic lactones with the multidrug transporters: the bases of the pharmacokinetics of lipid-like drugs. Curr Drug Metab 2009;10(3):272-88
   PubMed Web of Science ®Google Scholar
• Bassissi MF, Alvinerie M, Lespine A. Macrocyclic lactones: distribution in plasma lipoproteins of several animal species including humans. Comp Biochem Physiol C Toxicol Pharmacol 2004;138(4):437-44
   PubMed Web of Science ®Google Scholar
• Lespine A, Chanoit G, Bousquet-Melou A, et al. Contribution of lymphatic transport to the systemic exposure of orally administered moxidectin in conscious lymph duct-cannulated dogs. Eur J Pharm Sci 2006;27(1):37-43
   PubMed Web of Science ®Google Scholar
• Zulalian J, Stout SJ, daCunha AR, et al. Absorption, tissue distribution, metabolism, and excretion of moxidetin in cattle. J Agric Food Chem 1994;42(2):381-7
   Web of Science ®Google Scholar
• Lespine A, Ménez C, Bourguinat C, Prichard RK. P-glycoproteins and other ABC transporters in the pharmacology of anthelmintics: prospects for reversing transport-dependent anthelmintic resistance. Int J Parasitol Drugs Drug Resistance 2012;2:58-75
   PubMed Web of Science ®Google Scholar
• Shoop WL, Egerton JR, Eary CH, et al. Eprinomectin: a novel avermectin for use as a topical endectocide for cattle. Int J Parasitol 1996;26(11):1237-42
   PubMed Web of Science ®Google Scholar
• Escher BI, Berger C, Bramaz N, et al. Membrane-water partitioning, membrane permeability, and baseline toxicity of the parasiticides ivermectin, albendazole, and morantel. Environ Toxicol Chem 2008;27(4):909-18
   PubMed Web of Science ®Google Scholar
• Vellarkad N, Viswanadhan AK, Ghose AK, et al. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J Chem Inf Comp Sci 1989;29:163-72
   Google Scholar
• Lespine A, Alvinerie M, Sutra JF, et al. Influence of the route of administration on efficacy and tissue distribution of ivermectin in goat. Vet Parasitol 2005;128(3-4):251-60
   PubMed Web of Science ®Google Scholar
• Lifschitz A, Virkel G, Sallovitz J, et al. Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle. Vet Parasitol 2000;87(4):327-38
   PubMed Web of Science ®Google Scholar
• Hennessy DR, Alvinerie MR. Pharmacokinetics of the macrocyclic lactones: conventional wisdom and new paradigms. In: Vercruysse J, Rew RS, editors. Macrocyclic lactones and antiparasitic therapy. CAB International; New York: 2002. p. 97-123
   Google Scholar
• Lespine A, Sutra JF, Dupuy J, Alvinerie M. Eprinomectin in goat: assessment of subcutaneous administration. Parasitol Res 2003;89(2):120-2
   PubMed Web of Science ®Google Scholar
• Lallemand E, Lespine A, Alvinerie M, et al. Estimation of absolute oral bioavailability of moxidectin in dogs using a semi-simultaneous method: influence of lipid co-administration. J Vet Pharmacol Ther 2007;30(5):375-80
   PubMed Web of Science ®Google Scholar
• Kiki-Mvouaka S, Menez C, Borin C, et al. Role of P-glycoprotein in the disposition of macrocyclic lactones: a comparison between ivermectin, eprinomectin, and moxidectin in mice. Drug Metab Dispos 2010;38(4):573-80
   PubMed Web of Science ®Google Scholar
• Prichard RK, Steel JW, Lacey E, Hennessy DR. Pharmacokinetics of ivermectin in sheep following intravenous, intra-abomasal or intraruminal administration. J Vet Pharmacol Ther 1985;8(1):88-94
   PubMed Web of Science ®Google Scholar
• Hennessy DR, Page SW, Gottschall D. The behaviour of doramectin in the gastrointestinal tract, its secretion in bile and pharmacokinetic disposition in the peripheral circulation after oral and intravenous administration to sheep. J Vet Pharmacol Ther 2000;23(4):203-13
   PubMed Web of Science ®Google Scholar
• Lifschitz A, Virkel G, Ballent M, et al. Moxidectin and ivermectin metabolic stability in sheep ruminal and abomasal contents. J Vet Pharmacol Ther 2005;28(5):411-18
   PubMed Web of Science ®Google Scholar
• Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007;6(3):231-48
   PubMed Web of Science ®Google Scholar
• Cotreau MM, Warren S, Ryan JL, et al. The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans. J Clin Pharmacol 2003;43(10):1108-15
   PubMed Web of Science ®Google Scholar
• Korth-Bradley JM, Parks V, Chalon S, et al. The effect of a high-fat breakfast on the pharmacokinetics of moxidectin in healthy male subjects: a randomized phase I trial. Am J Trop Med Hyg 2012;86(1):122-5
   PubMed Web of Science ®Google Scholar
• Bassissi MF, Lespine A, Alvinerie M. Enhancement of oral moxidectin bioavailability in rabbits by lipid co-administration. Parasitol Res 2004;94(3):188-92
   PubMed Web of Science ®Google Scholar
• Wasan KM, Cassidy SM. Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J Pharm Sci 1998;87(4):411-24
   PubMed Web of Science ®Google Scholar
• Chapman MJ. Animal lipoproteins: chemistry, structure, and comparative aspects. J Lipid Res 1980;21(7):789-853
   PubMed Web of Science ®Google Scholar
• Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 2002;42(10):1122-33
   PubMed Web of Science ®Google Scholar
• Al-Azzam SI, Fleckenstein L, Cheng KJ, et al. Comparison of the pharmacokinetics of moxidectin and ivermectin after oral administration to beagle dogs. Biopharm Drug Dispos 2007;28(8):431-8
   PubMed Web of Science ®Google Scholar
• Bousquet-Melou A, Mercadier S, Alvinerie M, Toutain PL. Endectocide exchanges between grazing cattle after pour-on administration of doramectin, ivermectin and moxidectin. Int J Parasitol 2004;34(11):1299-307
   PubMed Web of Science ®Google Scholar
• Lloberas M, Alvarez L, Entrocasso C, et al. Comparative tissue pharmacokinetics and efficacy of moxidectin, abamectin and ivermectin concentrations in lambs infected with resistant nematodes: impact of drug treatments on parasite P-gp expression. Int J Parasitol DDR 2013;3:20-7
   Web of Science ®Google Scholar
• Perez R, Cabezas I, Garcia M, et al. Comparison of the pharmacokinetics of moxidectin (Equest) and ivermectin (Eqvalan) in horses. J Vet Pharmacol Ther 1999;22(3):174-80
   PubMed Web of Science ®Google Scholar
• Chiu SH, Taub R, Sestokas E, et al. Comparative in vivo and in vitro metabolism of ivermectin in steers, sheep, swine, and rat. Drug Metab Rev 1987;18(2-3):289-302
   PubMed Web of Science ®Google Scholar
• Vercruysse J, Deprez P, Everaert D, et al. Breed differences in the pharmacokinetics of ivermectin administered subcutaneously to Holstein and Belgian Blue calves. Vet Parasitol 2008;152(1-2):136-40
   PubMed Web of Science ®Google Scholar
• Sallovitz J, Lifschitz A, Imperiale F, et al. Breed differences on the plasma availability of moxidectin administered pour-on to calves. Vet J 2002;1:47-53
   Google Scholar
• Bengone-Ndong T, Ba MA, Kane Y, et al. Eprinomectin in dairy zebu Gobra cattle (Bos indicus): plasma kinetics and excretion in milk. Parasitol Res 2006;98(6):501-6
   PubMed Web of Science ®Google Scholar
• Craven J, Bjorn H, Hennessy D, et al. Pharmacokinetics of moxidectin and ivermectin following intravenous injection in pigs with different body compositions. J Vet Pharmacol Ther 2001;24(2):99-104
   PubMed Web of Science ®Google Scholar
• Craven J, Bjorn H, Hennessy DR, Friis C. The effects of body composition on the pharmacokinetics of subcutaneously injected ivermectin and moxidectin in pigs. J Vet Pharmacol Ther 2002;25(3):227-32
   PubMed Web of Science ®Google Scholar
• Bargues I, Lespine A, Toutain PL, Bousquet-Melou A. Influence of obesity on the pharmacokinetics of anthelmintic macrocyclic lactones in dogs J Vet Pharmacol Ther. 2009;32:161-2
   Google Scholar
• Lespine A, Sutra JF, Dupuy J, et al. The influence of parasitism on the pharmacokinetics of moxidectin in lambs. Parasitol Res 2004;93(2):121-6
   PubMed Web of Science ®Google Scholar
• Bassissi MF, Alvinerie M, Martin PG, et al. Influence of dyslipidemia on moxidectin distribution in plasma lipoproteins and on its pharmacokinetics. Pharm Res 2006;23(11):2672-80
   PubMed Web of Science ®Google Scholar
• Wasan KM. Modifications in plasma lipoprotein concentration and lipid composition regulate the biological activity of hydrophobic drugs. J Pharmacol Toxicol Methods 1996;36(1):1-11
   PubMed Web of Science ®Google Scholar
• Wasan KM, Kennedy AL, Cassidy SM, et al. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies. Antimicrob Agents Chemother 1998;42(12):3146-52
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Awni WM, Heim-Duthoy KL, et al. Alterations in cyclosporine pharmacokinetics after renal transplantation are linked to rapid increases in hematocrit, lipoproteins, and serum protein. Transplant Proc 1988;20(2 Suppl 2):485-6
   PubMed Web of Science ®Google Scholar
• Humberstone AJ, Porter CJ, Edwards GA, Charman WN. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. J Pharm Sci 1998;87(8):936-42
   PubMed Web of Science ®Google Scholar
• Humberstone AJ, Cowman AF, Horton J, Charman WN. Effect of altered serum lipid concentrations on the IC50 of halofantrine against Plasmodium falciparum. J Pharm Sci 1998;87(2):256-8
   PubMed Web of Science ®Google Scholar
• Venkataraman K, Narasimhan NI. Metabolism of [3H]-MK-0397 in cattle following a topical application (ADMES-3). n° 93993 Merck Research Laboratories 1995 New Jersey. 1995
   Google Scholar
• Ballent M, Lifschitz A, Virkel G, et al. Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: in vitro and in vivo assessments. Drug Metab Dispos 2006;34(3):457-63
   PubMed Web of Science ®Google Scholar
• Laffont CM, Toutain PL, Alvinerie M, Bousquet-Melou A. Intestinal secretion is a major route for parent ivermectin elimination in the rat. Drug Metab Dispos 2002;30(6):626-30
   PubMed Web of Science ®Google Scholar
• Perez M, Blazquez AG, Real R, et al. In vitro and in vivo interaction of moxidectin with BCRP/ABCG2. Chem Biol Interact 2009;180(1):106-12
   PubMed Web of Science ®Google Scholar
• Garrigues A, Loiseau N, Delaforge M, et al. Characterization of two pharmacophores on the multidrug transporter P-glycoprotein. Mol Pharmacol 2002;62(6):1288-98
   PubMed Web of Science ®Google Scholar
• Lespine A, Dupuy J, Orlowski S, et al. Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). Chem Biol Interact 2006;159(3):169-79
   PubMed Web of Science ®Google Scholar
• Brayden DJ, Griffin J. Avermectin transepithelial transport in MDR1- and MRP-transfected canine kidney monolayers. Vet Res Commun 2008;32(1):93-106
   PubMed Web of Science ®Google Scholar
• Smith AJ, van Helvoort A, van Meer G, et al. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem 2000;275(31):23530-9
   PubMed Web of Science ®Google Scholar
• Orlowski S, Comera C, Terce F, Collet X. Lipid rafts: dream or reality for cholesterol transporters? Eur Biophys J 2007;36(8):869-85
   PubMed Web of Science ®Google Scholar
• Le May C, Berger JM, Lespine A, et al. Transintestinal Cholesterol Excretion Is an Active Metabolic Process Modulated by PCSK9 and Statin Involving ABCB1. Arterioscler Thromb Vasc Biol 2013;33(7):1484-93
   PubMed Web of Science ®Google Scholar
• Yasuhisa K, Shin-ya M, Michinori M, Kazumitsu U. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci 2007;98(9):1303-10
   PubMed Web of Science ®Google Scholar
• Lifschitz A, Entrocasso C, Alvarez L, et al. Interference with P-glycoprotein improves ivermectin activity against adult resistant nematodes in sheep. Vet Parasitol 2010;172(3-4):291-8
   PubMed Web of Science ®Google Scholar
• Lifschitz A, Suarez VH, Sallovitz J, et al. Cattle nematodes resistant to macrocyclic lactones: comparative effects of P-glycoprotein modulation on the efficacy and disposition kinetics of ivermectin and moxidectin. Exp Parasitol 2010;125(2):172-8
   PubMed Web of Science ®Google Scholar
• Lespine A, Martin S, Dupuy J, et al. Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship. Eur J Pharm Sci 2007;30(1):84-94
   PubMed Web of Science ®Google Scholar
• Mealey KL. ABCG2 transporter: therapeutic and physiologic implications in veterinary species. J Vet Pharmacol Ther 2011;35(2):105-12
   PubMed Web of Science ®Google Scholar
• Jani M, Makai I, Kis E, et al. Ivermectin interacts with human ABCG2. J Pharm Sci 2010;100(1):94-7
   PubMed Web of Science ®Google Scholar
• Real R, Egido E, Perez M, et al. Involvement of breast cancer resistance protein (BCRP/ABCG2) in the secretion of danofloxacin into milk: interaction with ivermectin. J Vet Pharmacol Ther 2011;34(4):313-21
   PubMed Web of Science ®Google Scholar
• Olsen HG, Nilsen H, Hayes B, et al. Genetic support for a quantitative trait nucleotide in the ABCG2 gene affecting milk composition of dairy cattle. BMC Genet 2007;8:32
   PubMed Web of Science ®Google Scholar
• Schaeffer JM, Bergstrom AR, Turner MJ. MK-801 is a potent nematocidal agent. Characterization of MK-801 binding sites in Caenorhabditis elegans. Biochem J 1989;260(3):923-6
   PubMed Web of Science ®Google Scholar
• Lankas GR, Cartwright ME, Umbenhauer D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol 1997;143(2):357-65
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77(4):491-502
   PubMed Web of Science ®Google Scholar
• Ardelli BF, Stitt LE, Tompkins JB, Prichard RK. A comparison of the effects of ivermectin and moxidectin on the nematode Caenorhabditis elegans. Vet Parasitol 2009;165(1-2):96-108
   PubMed Web of Science ®Google Scholar
• Prichard RK, Ménez M, Lespine A. Moxidectin and the avermectins: consanguinity but not identity. Int J Parasitol Drugs Drug Resist 2012;2:134-53
   PubMed Web of Science ®Google Scholar
• Njue AI, Hayashi J, Kinne L, et al. Mutations in the extracellular domains of glutamate-gated chloride channel alpha3 and beta subunits from ivermectin-resistant Cooperia oncophora affect agonist sensitivity. J Neurochem 2004;89(5):1137-47
   PubMed Web of Science ®Google Scholar
• Hibbs RE, Gouaux E. Principles of activation and permeation in an anion-selective Cys-loop receptor. Nature 2011;474(7349):54-60
   PubMed Web of Science ®Google Scholar
• Menez C, Sutra JF, Prichard R, Lespine A. Relative neurotoxicity of ivermectin and moxidectin in Mdr1ab (-/-) mice and effects on mammalian GABA(A) channel activity. PLoS Negl Trop Dis 2012;6(11):e1883
   PubMed Web of Science ®Google Scholar
• Cisternino S, Mercier C, Bourasset F, et al. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res 2004;64(9):3296-301
   PubMed Web of Science ®Google Scholar
• Toutain PL, Campan M, Galtier P, Alvinerie M. Kinetic and insecticidal properties of ivermectin residues in the milk of dairy cows. J Vet Pharmacol Ther 1988;11(3):288-91
   PubMed Web of Science ®Google Scholar
• Cerkvenik-Flajs V, Grabnar I, Kozuh Erzen N, et al. Kinetics of abamectin disposition in blood plasma and milk of lactating dairy sheep and suckling lambs. J Agric Food Chem 2007;55(23):9733-8
   PubMed Web of Science ®Google Scholar
• Imperiale FA, Busetti MR, Suarez VH, Lanusse CE. Milk excretion of ivermectin and moxidectin in dairy sheep: assessment of drug residues during cheese elaboration and ripening period. J Agric Food Chem 2004;52(20):6205-11
   PubMed Web of Science ®Google Scholar
• Imperiale FA, Mottier L, Sallovitz JM, et al. Disposition of doramectin milk residues in lactating dairy sheep. J Agric Food Chem 2003;51(10):3185-90
   PubMed Web of Science ®Google Scholar
• Jonker JW, Merino G, Musters S, et al. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 2005;11(2):127-9
   PubMed Web of Science ®Google Scholar
• Alvinerie M, Sutra JF, Galtier P, Mage C. Pharmacokinetics of eprinomectin in plasma and milk following topical administration to lactating dairy cattle. Res Vet Sci 1999;67(3):229-32
   PubMed Web of Science ®Google Scholar
• Dupuy J, Chartier C, Sutra JF, Alvinerie M. Eprinomectin in dairy goats: dose influence on plasma levels and excretion in milk. Parasitol Res 2001;87(4):294-8
   PubMed Web of Science ®Google Scholar
• Hodoscek L, Grabnar I, Milcinski L, et al. Linearity of eprinomectin pharmacokinetics in lactating dairy sheep following pour-on administration: excretion in milk and exposure of suckling lambs. Vet Parasitol 2008;154(1-2):129-36
   PubMed Web of Science ®Google Scholar
• Dupuy J, Sutra JF, Alvinerie M, et al. Plasma and milk kinetic of eprinomectin and moxidectin in lactating water buffaloes (Bubalus bubalis). Vet Parasitol 2008;157(3-4):284-90
   PubMed Web of Science ®Google Scholar
• Bengoumi M, Hidane K, Bengone N, et al. Pharmacokinetics of eprinomectin in plasma and milk in lactating camels (Camelus dromedarius). Vet Res Commun 2007;31(3):317-22
   PubMed Web of Science ®Google Scholar
• Korth-Bradley JM, Parks V, Chalon S, et al. Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women. Antimicrob Agents Chemother 2011;55(11):5200-4
   PubMed Web of Science ®Google Scholar
• Ogbuokiri JE, Ozumba BC, Okonkwo PO. Ivermectin levels in human breastmilk. Eur J Clin Pharmacol 1993;45(4):389-90
   PubMed Web of Science ®Google Scholar
• Lloberas M, Alvarez L, Entrocasso C, et al. Measurement of ivermectin concentrations in target worms and host gastrointestinal tissues: influence of the route of administration on the activity against resistant Haemonchus contortus in lambs. Exp Parasitol 2012;131(3):304-9
   PubMed Web of Science ®Google Scholar
• Hartsel S, Bolard J. Amphotericin B: new life for an old drug. Trends Pharmacol Sci 1996;17(12):445-9
   PubMed Web of Science ®Google Scholar
• Bassissi F, Lespine A, Alvinerie M. Assessment of a liposomal formulation of ivermectin in rabbit after a single subcutaneous administration. Parasitol Res 2006;98(3):244-9
   PubMed Web of Science ®Google Scholar
• Kurzchalia TV, Ward S. Why do worms need cholesterol? Nat Cell Biol 2003;5(8):684-8
   PubMed Web of Science ®Google Scholar
• Jeusette IC, Lhoest ET, Istasse LP, Diez MO. Influence of obesity on plasma lipid and lipoprotein concentrations in dogs. Am J Vet Res 2005;66(1):81-6
   PubMed Web of Science ®Google Scholar
• Lifschitz A, Entrocasso C, Alvarez L, et al. Interference with P-glycoprotein improves ivermectin activity against adult resistant nematodes in sheep. Vet Parasitol 2010;172(3):291-8
   PubMed Web of Science ®Google Scholar
• Cornaire G, Woodley J, Hermann P, et al. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm 2004;278(1):119-31
   PubMedGoogle Scholar
• Seelig A, Gerebtzoff G. Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding. Expert Opin Drug Metab Toxicol 2006;2(5):733-52
   PubMed Web of Science ®Google Scholar
• Batrakova EV, Li S, Miller DW, Kabanov AV. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm Res 1999;16(9):1366-72
   PubMed Web of Science ®Google Scholar
• Tso P, Gollamudi SR. Pluronic L-81: a potent inhibitor of the transport of intestinal chylomicrons. Am J Physiol 1984;247(1 Pt 1):G32-6
   PubMed Web of Science ®Google Scholar
• Bartley DJ, Morrison AA, Dupuy J, et al. Influence of Pluronic 85 and ketoconazole on disposition and efficacy of ivermectin in sheep infected with a multiple resistant Haemonchus contortus isolate. Vet Parasitol 2012;187(3-4):464-72
   PubMed Web of Science ®Google Scholar
• Pérez R, Cabezas I, Godoy C, et al. Pharmacokinetics of doramectin and ivermectin after oral administration in horses. Vet J 2002;163(2):161-7
   PubMed Web of Science ®Google Scholar